Last reviewed · How we verify
2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine (CHLORPROETHAZINE)
2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine (generic name: CHLORPROETHAZINE) is a chlorproethazine drug. It is currently in Phase 2 development.
Chlorproethazine works by blocking the action of dopamine at the D(3) receptor, which can help regulate various physiological processes.
2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine, also known as Chlorproethazine, is a small molecule targeting the D(3) dopamine receptor. It belongs to the chlorproethazine drug class but its commercial status, including patent and generic availability, is unknown. The FDA approval status for Chlorproethazine is also unclear. As a dopamine receptor antagonist, it is likely used to treat conditions related to dopamine dysregulation, but specific approved indications are not available. Further research is needed to understand its pharmacokinetic properties and safety considerations.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CHLORPROETHAZINE |
|---|---|
| Drug class | chlorproethazine |
| Target | D(4) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine dopamine as a key that unlocks a door. The D(3) receptor is like the lock on that door. When dopamine binds to the receptor, it can trigger various effects in the body. Chlorproethazine acts like a lockout device, preventing dopamine from binding to the receptor and thereby reducing its effects.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine CI brief — competitive landscape report
- 2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine updates RSS · CI watch RSS
Frequently asked questions about 2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine
What is 2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine?
How does 2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine work?
What is the generic name of 2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine?
What drug class is 2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine in?
What development phase is 2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine in?
What does 2-Chloro-10-(3-Diethylaminopropyl)Phenothiazine target?
Related
- Drug class: All chlorproethazine drugs
- Target: All drugs targeting D(4) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing